Takeda Pharmaceutical Company Limited

Terumo Kabushiki Kaisha

Other

Terumo Corporation

Naoki Ishii

Satoshi Yamamoto

Tsuneo Oda

Junya Shirai

Shoji Fukumoto

Yoshiyuki Fukase

Yoshihide Tomata

Atsuko Ochida

Mitsunori Kono

Hidekazu Tokuhara

Takashi Imada

Tomoya Yukawa

Michiko Tawada

Masato Yoshikawa

Masaki Daini

Ayumu Sato

Yusuke Sasaki

Hiroshi Nara

Akira Kaieda

Hideaki Shibata

Kenichi Shimura

Masashi Toyofuku

Satoshi Sawada

Kousuke Hidaka

Takashi Kaneko

Makoto Onishi

Hideki Yamamoto

Shin Sumimoto

Ichiro Nagao

Hiroyuki Watanabe

Kenji Ishikawa

Yasunobu Zushi

Naoya Shimada

Hideaki Kitou

Taku Aoike

Hideyuki Togawa

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

Heterocyclic amide compounds having an RORvt inhibitory action

A medicine injection catheter includes: a catheter main body formed with a medicine supply lumen; a tubular body connected to the distal end of the catheter main body and having a lumen communicating with the medicine supply lumen; an injection needle connected to the tubular body; a tubular cover member that accommodates the tubular body and that is configured to be advanced and retracted in the axial direction of the catheter main body between a first position where a distal end of the injection needle is accommodated in the tubular cover and a second position where the distal end of the injection needle protrudes forward from the inside space; a closing member to close and open the lumen of the tubular body, a motion conversion mechanism which converts advancing/retracting motion of the cover member into movement of the closing member to close the lumen of the tubular body.

Medicine injection catheter and medicine injection system

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. In the formula (I), each symbol is as defined in the specification. 

Heterocyclic amide compounds having RORyT inhibitory action

A drug supply device for supplying drug to a living body surface that includes a shaft and a drug holding sheet attached to the distal end of the shaft. The drug holding sheet has a first face that faces distally and a second face opposite the first face that faces proximally when the drug holding sheet is expanded. The drug holding sheet includes folded portions that fold such that the first face is positioned to face radially inward while exposing the second face to an outside environment when the drug holding sheet is in a folded state. A drug is applied on the first face of the drug holding sheet. The drug supply device includes an expandable member on the second face of the drug holding sheet. The expandable member is expandable to cause the drug holding sheet to expand from the folded state into the expanded state.

Drug supply device

A medical apparatus for joining body lumens in a living body includes a puncture member having a lumen, a distal opening portion and a needle tip at the distal end of the lumen. The needle tip can puncture a tube wall of the body lumen to form a puncture site. The medical apparatus includes a tubular member in the lumen of the puncture member that expands radially outward and contracts radially inward and a plunger movable relative to the puncture member to release the tubular member from the distal opening portion of the puncture member. The tubular member expands to be fixed to the puncture site when the tubular member is released from the distal opening portion of the puncture member.

Medical apparatus

Amide compound

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Provided are heterocyclic compounds having a ROR&#x3b3;t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. wherein each symbol is as defined in the specification.

The problem of the present invention is to provide a compound having a superior ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The present invention provides a heterocyclic compound having a ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Naoki Ishii